DNA methylation signature as a biomarker of major neuropsychiatric disorders
| Autor: | Shirvani Farsani, Zeinab, Maloum, Zahra, Bagheri Hosseinabadi, Zahra, Vilor Tejedor, Natàlia, 1988, Sadeghi, Iman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Bipolar Disorder
Autism Spectrum Disorder Autism Major depressive disorder Bioinformatics 03 medical and health sciences 0302 clinical medicine SDG 3 - Good Health and Well-being mental disorders medicine Humans ADHD Bipolar disorder Epigenetics Biological Psychiatry Brain disease Depressive Disorder Major DNA methylation business.industry medicine.disease 030227 psychiatry Psychiatry and Mental health Biomarker Schizophrenia Autism spectrum disorder Attention Deficit Disorder with Hyperactivity Bipolar business 030217 neurology & neurosurgery Biomarkers |
| Popis: | DNA methylation is a broadly-investigated epigenetic modification that has been considered as a heritable and reversible change. Previous findings have indicated that DNA methylation regulates gene expression in the central nervous system (CNS). Also, disturbance of DNA methylation patterns has been associated with destructive consequences that lead to human brain diseases such as neuropsychiatric disorders (NPDs). In this review, we comprehensively discuss the mechanism and function of DNA methylation and its most recent associations with the pathology of NPDs-including major depressive disorder (MDD), schizophrenia (SZ), autism spectrum disorder (ASD), bipolar disorder (BD), and attention/deficit hyperactivity disorder (ADHD). We also discuss how heterogeneous findings demand further investigations. Finally, based on the recent studies we conclude that DNA methylation status may have implications in clinical diagnostics and therapeutics as a potential epigenetic biomarker of NPDs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|